To determine values for home blood pressure (HBP) during pregnancy, nurses taught 45 healthy pregnant women to use a HBP method for 1 week before 15 weeks of gestation, between weeks 15 and 27, and after 28 weeks for the last 3 months of gestation. HBP values were significantly lower during the second trimester and higher during the last trimester (102 Ϯ 8/59 Ϯ 7* , 101 Ϯ 8/57 Ϯ 8*, 105 Ϯ 8*/62 Ϯ 9* mm Hg;*PϽ 0.05) than during other trimesters. Heart rate increased significantly during the pregnancy. The present study suggests upper limits 
D
uring their pregnancies, 10% to 15% of women exhibit one or more high blood pressure (BP) values. Hypertension is a major risk factor for both mother and fetus. More than one high BP measurement is required to confirm hypertension because white coat effect is a frequent occurrence, especially during pregnancy. Moreover, the situation is complicated by the fact that BP decreases during the early stages of normal pregnancy. Therefore, reference BP values in pregnant and nonpregnant women are not comparable.
Automatic devices are now available for repeatedly measuring BP values during pregnancy and for helping to eliminate the white coat effect, so as to prevent excessive antihypertensive treatment that may be harmful to the fetus. 1 Reference values of ambulatory BP measurement (ABPM) were recently published, [2] [3] [4] [5] [6] but this method is costly and is not frequently used by general practitioners or obstetricians during pregnancy. Home BP (HBP) is less expensive and more easily used, particularly by obstetricians. However, few HBP devices have been validated. 7 The aim of this study was to determine home BP values during the three gestational 3-month periods in women with normal pregnancies.
Subjects and Methods

Protocol
This multicenter study was conducted in six French hospitals. In each center, inclusion criteria were checked by an obstetrician, and one nurse taught pregnant women how to use the HBP device (Hestia Pharma D2, Mannheim, Germany, validated in the Hypertension Optimal Treatment [HOT] study) 8 and how to fill in the case report form. The HPB apparatus was calibrated with a mercury sphygmomanometer (mean of two measurements). The BP had to be measured in seated position, three times at 1-min intervals before breakfast and after dinner from Monday evening to Saturday evening. The Monday evening values were excluded from final analysis. This HBP protocol was performed three times: 1) before 15 weeks of gestation for the first 3-month period (mean 10); 2) between weeks 15 to 27 for the second 3-month period (mean 21); and 3) after 28 weeks for the last 3-month period (mean 32). Only data from pregnant women who completed all three timeperiod reports were analyzed.
Population
Only healthy pregnant women (both nulliparous and multiparous) with no history of hypertension or obesity (body mass index [BMI] Ͻ30 kg/m 2 ) who could measure their BP for 1 week during each 3-month period were included after giving their informed consent. After the childbirth, the obstetrician verified that the pregnancy had been normal without hypertension, proteinuria, or delivery of a low-birth-weight baby.
A total of 66 women entered this study but only 45 had the three good-quality monitorings in the predefined peri-ods as required. The other 21 women were excluded because the pregnancy or the birth weight were not considered normal by the obstetrician or because the recordings were not performed during the three predefined gestational periods
The 45 healthy pregnant women analyzed in this study were aged 30 years (range 23 to 37 years). Birth weight was 3460 Ϯ 440 g (range 2650 to 4360 g).
Statistical Analysis
Results were expressed as mean Ϯ 1 standard deviation. The three HBP monitoring periods were compared by analysis of variance for repeated values. The Student t test was performed to compare morning and evening HBP. P values Ͻ .05 were considered to indicate statistical significance.
Reference values were defined as mean ϩ 2 standard deviations and from the 95th percentile of these normal values.
Results
Diastolic BP was significantly lower during the first two trimesters of the pregnancy (102 Ϯ 8/59* Ϯ 7 mm Hg, and 101 Ϯ 8/57* Ϯ 8 mm Hg, respectively). Systolic and diastolic BP increased during the third trimester (105* Ϯ 8/62* Ϯ 9 mm Hg; *P Ͻ .05 between the trimesters) compared with the two other trimesters. Heart rate increased significantly during the pregnancy (from 81* Ϯ 9 to 85* Ϯ 9 and 88* Ϯ 10 beats/min; *P Ͻ .05 between the trimesters).
Evening HBP was higher than in the morning during the first and second trimesters (morning: 101* Ϯ 8/59 Ϯ 8, 100* Ϯ 9/57 Ϯ 9 and 105 Ϯ 9/62 Ϯ 9 mm Hg; evening: 103 Ϯ 8/60 Ϯ 7, 102 Ϯ 8/58 Ϯ 8 and 106 Ϯ 8/62 Ϯ 8 mm Hg during the 3-month gestational periods; *P Ͻ .05 between morning and evening).
In one center, we compared office BP with HBP. Office BP values were higher than HBP at all stages (115 Ϯ 11/65 Ϯ 7 v 107 Ϯ 9/61 Ϯ 6 mm Hg; 113 Ϯ 13/64 Ϯ 6 v 109 Ϯ 7/61 Ϯ 9 mm Hg and 113 Ϯ 11/66 Ϯ 7 v 111 Ϯ 7/65 Ϯ 8 mm Hg during the 3-month gestational periods).
Reference normal values, for the upper normal limits of HBP (and heart rate) during the gestational 3-month periods were calculated with two different methods: mean ϩ 2 standard deviations: 118/73 (99), 117/73 (103), and 121/80 mm Hg (108 beats/min), and 95th percentile: 116/ 70, 113/70, and 118/76 mm Hg with comparable results (Table 1) .
Discussion
This study describes the range of normal values for systolic and diastolic home BP recorded by a semiautomatic oscillometric device in a cohort of normal pregnant women.
At the beginning of this study, none of the available HBP devices had been validated for monitoring during pregnancy. We chose the Hestia Pharm D2 device because it had been validated in essential hypertension and used in a large study, the Hypertension Optimal Treatment Study. 8 There is currently a paucity of data validating the use of these devices in pregnancy. Although some HBP devices have been validated during pregnancy, they are unreliable if women develop preeclampsia. 9, 10 It is not yet clear whether preeclampsia per se or the degree of hypertension is responsible for the low performance of these HBP devices. It would appear from the most recent recommendations 7 that if a device passes the standard assessment using British Hypertension Society (BHS) or Association for the Advancement of Medical Information (AAMI) protocols, it will go on to pass the assessment for the use during pregnancy. The same cannot be said for preeclampsia; however, none of the women in our study developed preeclampsia or delivered low-birth-weight infants.
To optimize our data, we chose a longitudinal study in which the group of women was very homogenous and in which all women were required to monitor their BP at home at the three trimesters of pregnancy. Although we included only 45 women and these data are too limited to provide reference HBP values, we were able to detect statistical differences between HBP at the three trimesters. As previously noted with ambulatory or clinical measurements, a very early fall in BP appears that persists until the second trimester, before a rise occurs at the end of the pregnancy. [2] [3] [4] [5] [6] 11 In nonpregnant women, international recommendations give comparable normal limits for ABPM and HBP (Ͻ135/85 mm Hg). 12 Our upper limits of normal values, whether defined as mean ϩ 2 SD or as the 95th percentile, are lower at all stages of the pregnancy in pregnant women than in nonpregnant women. Moreover, our HBP normal limits are lower than those previously published with daytime ABMP [2] [3] [4] [5] [6] and office BP ( Table 2 ). These differences between HBP and daytime ABPM were also reported in some studies in essential hypertension. 13 The upper limits for normal home BP levels in our study are also lower than those recently published for HBP by Lo et al 10 (Table 2) , but these values are explained by the differences in inclusion criteria and methods to measure home BP. In the study by Lo et al, HBP was measured four times over only 24 h versus six times per day during 6 days in this study. Their method is not in accordance with the recommendations for HBP monitoring, 14 and it is known that BP is higher on the first day of home monitoring (which we excluded in our study). Moreover, in their healthy pregnant cohort, six women had gestational hypertension and two preeclampsia, and one woman was treated at the time of her postpartum monitoring. Of the infants, 12% had a birth weight in less than the 10th percentile.
We conclude that HBP is a relevant and reproducible method to measure daytime BP at home during pregnancy. 15 Although the interpretation of these normal values is limited by the small number of pregnant women, this first study confirmed the observation that we need to compare HBP results with adequate reference BP values because self-measured BP gives lower values than clinical BP measurement. This method may be useful to confirm hypertension during pregnancy and to prevent the damages associated with excessive antihypertensive treatment. 
